How we’re helping in South Africa

Supporting victims of sexual violence and pushing for better access to lifesaving drugs

South Africa 2020 © Tadeu Andre/MSF
Click to hide Text

How MSF is fighting COVID-19 in South Africa

At the end of February, we closed our activities in Ngwelezana Tertiary hospital in KwaZulu-Natal Province, where a team of our doctors and nurses worked in a 113-bed COVID-19 field hospital. Anticipating a new wave, our teams across the country are now actively working towards a state of readiness in areas already hit hard, drawing on our experience and focusing on care inside hospitals.

Learn more about how we are responding to the coronavirus pandemic in South Africa.

In South Africa, Doctors Without Borders/Médecins Sans Frontières (MSF) continues to develop innovative strategies to prevent and treat HIV and tuberculosis (TB) and provide comprehensive care for victims of sexual violence.

What is happening in South Africa?

In 2019, our large-scale community HIV/TB project in King Cetshwayo district, KwaZulu-Natal, run in collaboration with the Department of Health, became the first in South Africa to reach the UNAIDS 90-90-90 targets. A survey supported by Epicentre, MSF’s epidemiological research arm, revealed that 90 percent of people living with HIV knew their status, 94 percent of those were on antiretroviral treatment, and 95 percent of people on treatment had a suppressed viral load. In response to the growing phenomenon of disengagement from HIV care, we have developed services in the urban slum of Khayelitsha to encourage patients, including those with advanced HIV, to restart treatment. In Khayelitsha and rural Eshowe, where young people, particularly women, remain highly vulnerable to HIV, we offered preventive treatment to 204 patients. We also continued to develop different HIV screening strategies, including distributing over 30,000 oral self-testing kits.

on first-line ARV treatment in 2019
started on treatment for TB
treated after incidents of sexual violence

How we're helping in South Africa

MSF supports two multinational, multi-site clinical trials: TB PRACTECAL and endTB, which aim to find shorter, less toxic and more effective treatment regimens for multidrug-resistant TB. In 2019, the endTB trial enrolled its 48th patient at the Khayelitsha site, and two new sites, Durban and Johannesburg, were added to the TB PRACTECAL trial, with a total of 70 patients enrolled by the end of the year. We welcomed the registration of the newer TB drug delamanid, and we continue to push for improved treatment for the disease nationally. Learn how you can best help in South African and other countries.


MSF projects in South Africa

View map

Sexual violence

MSF works with the provincial health department to provide victims of sexual violence with essential medical and psychosocial care through community clinics known as Kgomotso Care Centres on South Africa’s platinum mining belt. In 2019, we handed over two of the four clinics to the department. We also launched initiatives to identify victims of sexual violence, for example through our school health program, which reached 26,000 students. Community-based initiatives accounted for at least 160 of the 1,294 new patients seen in 2019.

To meet the high demand for pregnancy termination, we trained 23 health department providers in safe abortion care. In MSF-supported facilities, an average of 209 abortions were performed monthly in 2019. Please donate to support our work in South Africa and other countries around the world now.


In Tshwane, we opened a hub offering medical and psychosocial care to migrants, refugees and asylum seekers, who struggle to access public health services under South Africa’s increasingly restrictive migration policies. In 2019, 668 people received medical and psychological support and 456 attended group mental health sessions. In addition, our emergency teams responded to episodes of xenophobic violence against migrants in three provinces.

Access to medicines

We continue to call for wider availability of lifesaving drugs by addressing the patent, registration, and financial barriers that prevent their supply. Through a national access program set up by MSF, we donated 610 courses of flucytosine—an effective cryptococcal meningitis treatment not yet registered for use in South Africa—to 15 specialist facilities across the country. The program seeks to build evidence to support its registration as an essential medicine.